Celltrion Secures Deal With PBM Express Scripts For Subcutaneous Infliximab

The Agreement Gives The Drug Access To Nearly 22 Million Patients In The US

Celltrion unveils its agreement with the PBM Express Scripts that will place its Zymfentra subcutaneous infliximab on its preferred formulary after alluding to the deal in an earlier notice. 

Celltrion website homepage. Celltrion logo
• Source: Shutterstock

Celltrion USA has signed an agreement with the pharmacy benefit manager Express Scripts that will place the company’s subcutaneous formulation of infliximab on the Express Scripts National Preferred Formulary. While Express Scripts handles health plans for more than 100 million Americans, the PBM gave the biosimilar Preferred Brand Access that will reach 21.9 million insured customers.

Marketed under the name Zymfentra, the drug is the first US Food and Drug Administration approved subcutaneous formulation of infliximab.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By 

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Amgen Stands Firm On IV Checkpoint Inhibitor Biosimilars

 
• By 

Amgen continues to advance its intravenous biosimilar programs for key immuno-oncology agents, including its ABP 234 biosimilar to Keytruda and ABP 206 biosimilar to Opdivo, despite growing interest in subcutaneous formulations enabled by hyaluronidase technology.

‘Concrete Solutions, Not Big Words’ – Samsung Bioepis Suggests European Improvements For Biosimilars

 
• By 

While biosimilars have seen success in Europe, there are still plenty of areas in which policy improvements could solve problems for the market, according to a new Samsung Bioepis white paper. Adam Levysohn, the firm’s local head of commercial strategy, talks about the proposals.